| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
| N_HPV: HPV-infected normal cervix |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer |
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions |
| MSI-H: Microsatellite-high colorectal cancer |
| MSS: Microsatellite stable colorectal cancer |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias |
| LGIN: Low-grade intraepithelial neoplasias |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ |
| IAC: Invasive lung adenocarcinoma |
| MIA: Minimally invasive adenocarcinoma |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia |
| NEOLP: Non-erosive oral lichen planus |
| OSCC: Oral squamous cell carcinoma |
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma |
| SCCIS:squamous cell carcinoma in situ |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis |
| PTC: Papillary thyroid cancer |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0060444 | Colorectum | MSS | branching involved in mammary gland duct morphogenesis | 10/3467 | 22/18723 | 3.42e-03 | 2.56e-02 | 10 |
| GO:0060603 | Colorectum | MSS | mammary gland duct morphogenesis | 12/3467 | 30/18723 | 5.00e-03 | 3.46e-02 | 12 |
| GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
| GO:0050678 | Colorectum | MSS | regulation of epithelial cell proliferation | 90/3467 | 381/18723 | 6.92e-03 | 4.45e-02 | 90 |
| GO:00487324 | Colorectum | FAP | gland development | 103/2622 | 436/18723 | 3.61e-08 | 3.12e-06 | 103 |
| GO:00485113 | Colorectum | FAP | rhythmic process | 72/2622 | 298/18723 | 1.67e-06 | 6.99e-05 | 72 |
| GO:00605602 | Colorectum | FAP | developmental growth involved in morphogenesis | 58/2622 | 234/18723 | 7.21e-06 | 2.19e-04 | 58 |
| GO:00226123 | Colorectum | FAP | gland morphogenesis | 34/2622 | 118/18723 | 2.13e-05 | 5.12e-04 | 34 |
| GO:00605622 | Colorectum | FAP | epithelial tube morphogenesis | 71/2622 | 325/18723 | 7.23e-05 | 1.33e-03 | 71 |
| GO:00165701 | Colorectum | FAP | histone modification | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
| GO:0023061 | Colorectum | FAP | signal release | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
| GO:00063253 | Colorectum | FAP | chromatin organization | 84/2622 | 409/18723 | 1.62e-04 | 2.47e-03 | 84 |
| GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
| GO:00614583 | Colorectum | FAP | reproductive system development | 85/2622 | 427/18723 | 4.30e-04 | 5.13e-03 | 85 |
| GO:00097913 | Colorectum | FAP | post-embryonic development | 23/2622 | 80/18723 | 4.51e-04 | 5.32e-03 | 23 |
| GO:00486083 | Colorectum | FAP | reproductive structure development | 84/2622 | 424/18723 | 5.40e-04 | 6.10e-03 | 84 |
| GO:00017632 | Colorectum | FAP | morphogenesis of a branching structure | 44/2622 | 196/18723 | 8.79e-04 | 9.01e-03 | 44 |
| GO:00308793 | Colorectum | FAP | mammary gland development | 33/2622 | 137/18723 | 1.07e-03 | 1.04e-02 | 33 |
| GO:00506732 | Colorectum | FAP | epithelial cell proliferation | 84/2622 | 437/18723 | 1.39e-03 | 1.25e-02 | 84 |
| GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| KDM5B | MES | Cervix | CC | AC016831.1,SNAPC1,ITPRID2, etc. | 7.14e-01 |  |
| KDM5B | CAF | Pancreas | ADJ | GPR137C,ZNF335,TCEAL5, etc. | 7.22e-03 |  |
| KDM5B | PSC | Pancreas | Healthy | GPR137C,ZNF335,TCEAL5, etc. | 2.33e-02 |  |
| KDM5B | INCAF | Pancreas | Healthy | GPR137C,ZNF335,TCEAL5, etc. | 1.70e-02 |  |
| KDM5B | MSC | Pancreas | PanIN | GPR137C,ZNF335,TCEAL5, etc. | 3.96e-02 |  |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KDM5B | SNV | Missense_Mutation | rs777450660 | c.378N>C | p.Lys126Asn | p.K126N | Q9UGL1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| KDM5B | SNV | Missense_Mutation | | c.365A>G | p.His122Arg | p.H122R | Q9UGL1 | protein_coding | deleterious(0.05) | possibly_damaging(0.783) | TCGA-A1-A0SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
| KDM5B | SNV | Missense_Mutation | | c.3241N>G | p.Arg1081Gly | p.R1081G | Q9UGL1 | protein_coding | tolerated(0.07) | benign(0.081) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
| KDM5B | SNV | Missense_Mutation | | c.2530N>C | p.Glu844Gln | p.E844Q | Q9UGL1 | protein_coding | deleterious(0.03) | possibly_damaging(0.698) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| KDM5B | SNV | Missense_Mutation | | c.1762N>G | p.Leu588Val | p.L588V | Q9UGL1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| KDM5B | SNV | Missense_Mutation | | c.257G>A | p.Arg86His | p.R86H | Q9UGL1 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| KDM5B | SNV | Missense_Mutation | rs760532266 | c.2134N>A | p.Asp712Asn | p.D712N | Q9UGL1 | protein_coding | tolerated(0.18) | benign(0.311) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| KDM5B | SNV | Missense_Mutation | rs757818490 | c.1817G>A | p.Arg606Gln | p.R606Q | Q9UGL1 | protein_coding | deleterious(0) | possibly_damaging(0.754) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KDM5B | SNV | Missense_Mutation | rs370972925 | c.881N>A | p.Arg294His | p.R294H | Q9UGL1 | protein_coding | deleterious(0.01) | probably_damaging(0.972) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| KDM5B | SNV | Missense_Mutation | novel | c.1596N>G | p.Phe532Leu | p.F532L | Q9UGL1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |